Long-term outcome of stereotactic brachytherapy with temporary Iodine-125 seeds in patients with WHO grade II gliomas
Abstract Background This long-term retrospective analysis aimed to investigate the outcome and toxicity profile of stereotactic brachytherapy (SBT) in selected low-grade gliomas WHO grade II (LGGII) in a large patient series. Methods This analysis comprised 106 consecutive patients who received SBT...
| Main Authors: | , , , , , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
BMC
2020-12-01
|
| Series: | Radiation Oncology |
| Subjects: | |
| Online Access: | https://doi.org/10.1186/s13014-020-01719-9 |
| _version_ | 1818350614600482816 |
|---|---|
| author | Juliana Watson Alexander Romagna Hendrik Ballhausen Maximilian Niyazi Stefanie Lietke Sebastian Siller Claus Belka Niklas Thon Silke Birgit Nachbichler |
| author_facet | Juliana Watson Alexander Romagna Hendrik Ballhausen Maximilian Niyazi Stefanie Lietke Sebastian Siller Claus Belka Niklas Thon Silke Birgit Nachbichler |
| author_sort | Juliana Watson |
| collection | DOAJ |
| description | Abstract Background This long-term retrospective analysis aimed to investigate the outcome and toxicity profile of stereotactic brachytherapy (SBT) in selected low-grade gliomas WHO grade II (LGGII) in a large patient series. Methods This analysis comprised 106 consecutive patients who received SBT with temporary Iodine-125 seeds for histologically verified LGGII at the University of Munich between March 1997 and July 2011. Investigation included clinical characteristics, technical aspects of SBT, the application of other treatments, outcome analyses including malignization rates, and prognostic factors with special focus on molecular biomarkers. Results For the entire study population, the 5- and 10-years overall survival (OS) rates were 79% and 62%, respectively, with a median follow-up of 115.9 months. No prognostic factors could be identified. Interstitial radiotherapy was applied in 51 cases as first-line treatment with a median number of two seeds (range 1–5), and a median total implanted activity of 21.8 mCi (range 4.2–43.4). The reference dose average was 54.0 Gy. Five- and ten-years OS and progression-free survival rates after SBT were 72% and 43%, and 40% and 23%, respectively, with a median follow-up of 86.7 months. The procedure-related mortality rate was zero, although an overall complication rate of 16% was registered. Patients with complications had a significantly larger tumor volume (p = 0.029). Conclusion SBT is a minimally invasive treatment modality with a favorable outcome and toxicity profile. It is both an alternative primary treatment method as well as an adjunct to open tumor resection in selected low-grade gliomas. |
| first_indexed | 2024-12-13T18:24:39Z |
| format | Article |
| id | doaj.art-86d7645bf6c24605ac37bbc044a71692 |
| institution | Directory Open Access Journal |
| issn | 1748-717X |
| language | English |
| last_indexed | 2024-12-13T18:24:39Z |
| publishDate | 2020-12-01 |
| publisher | BMC |
| record_format | Article |
| series | Radiation Oncology |
| spelling | doaj.art-86d7645bf6c24605ac37bbc044a716922022-12-21T23:35:38ZengBMCRadiation Oncology1748-717X2020-12-0115111010.1186/s13014-020-01719-9Long-term outcome of stereotactic brachytherapy with temporary Iodine-125 seeds in patients with WHO grade II gliomasJuliana Watson0Alexander Romagna1Hendrik Ballhausen2Maximilian Niyazi3Stefanie Lietke4Sebastian Siller5Claus Belka6Niklas Thon7Silke Birgit Nachbichler8Department of Radiation Oncology, University Hospital, LMU MunichDepartment of Neurosurgery, München Klinik BogenhausenDepartment of Radiation Oncology, University Hospital, LMU MunichDepartment of Radiation Oncology, University Hospital, LMU MunichDepartment of Neurosurgery, University Hospital, LMU MunichDepartment of Neurosurgery, University Hospital, LMU MunichDepartment of Radiation Oncology, University Hospital, LMU MunichDepartment of Neurosurgery, University Hospital, LMU MunichDepartment of Radiation Oncology, University Hospital, LMU MunichAbstract Background This long-term retrospective analysis aimed to investigate the outcome and toxicity profile of stereotactic brachytherapy (SBT) in selected low-grade gliomas WHO grade II (LGGII) in a large patient series. Methods This analysis comprised 106 consecutive patients who received SBT with temporary Iodine-125 seeds for histologically verified LGGII at the University of Munich between March 1997 and July 2011. Investigation included clinical characteristics, technical aspects of SBT, the application of other treatments, outcome analyses including malignization rates, and prognostic factors with special focus on molecular biomarkers. Results For the entire study population, the 5- and 10-years overall survival (OS) rates were 79% and 62%, respectively, with a median follow-up of 115.9 months. No prognostic factors could be identified. Interstitial radiotherapy was applied in 51 cases as first-line treatment with a median number of two seeds (range 1–5), and a median total implanted activity of 21.8 mCi (range 4.2–43.4). The reference dose average was 54.0 Gy. Five- and ten-years OS and progression-free survival rates after SBT were 72% and 43%, and 40% and 23%, respectively, with a median follow-up of 86.7 months. The procedure-related mortality rate was zero, although an overall complication rate of 16% was registered. Patients with complications had a significantly larger tumor volume (p = 0.029). Conclusion SBT is a minimally invasive treatment modality with a favorable outcome and toxicity profile. It is both an alternative primary treatment method as well as an adjunct to open tumor resection in selected low-grade gliomas.https://doi.org/10.1186/s13014-020-01719-9Stereotactic brachytherapyIodine-125 seedsGrade II gliomaLow-grade glioma |
| spellingShingle | Juliana Watson Alexander Romagna Hendrik Ballhausen Maximilian Niyazi Stefanie Lietke Sebastian Siller Claus Belka Niklas Thon Silke Birgit Nachbichler Long-term outcome of stereotactic brachytherapy with temporary Iodine-125 seeds in patients with WHO grade II gliomas Radiation Oncology Stereotactic brachytherapy Iodine-125 seeds Grade II glioma Low-grade glioma |
| title | Long-term outcome of stereotactic brachytherapy with temporary Iodine-125 seeds in patients with WHO grade II gliomas |
| title_full | Long-term outcome of stereotactic brachytherapy with temporary Iodine-125 seeds in patients with WHO grade II gliomas |
| title_fullStr | Long-term outcome of stereotactic brachytherapy with temporary Iodine-125 seeds in patients with WHO grade II gliomas |
| title_full_unstemmed | Long-term outcome of stereotactic brachytherapy with temporary Iodine-125 seeds in patients with WHO grade II gliomas |
| title_short | Long-term outcome of stereotactic brachytherapy with temporary Iodine-125 seeds in patients with WHO grade II gliomas |
| title_sort | long term outcome of stereotactic brachytherapy with temporary iodine 125 seeds in patients with who grade ii gliomas |
| topic | Stereotactic brachytherapy Iodine-125 seeds Grade II glioma Low-grade glioma |
| url | https://doi.org/10.1186/s13014-020-01719-9 |
| work_keys_str_mv | AT julianawatson longtermoutcomeofstereotacticbrachytherapywithtemporaryiodine125seedsinpatientswithwhogradeiigliomas AT alexanderromagna longtermoutcomeofstereotacticbrachytherapywithtemporaryiodine125seedsinpatientswithwhogradeiigliomas AT hendrikballhausen longtermoutcomeofstereotacticbrachytherapywithtemporaryiodine125seedsinpatientswithwhogradeiigliomas AT maximilianniyazi longtermoutcomeofstereotacticbrachytherapywithtemporaryiodine125seedsinpatientswithwhogradeiigliomas AT stefanielietke longtermoutcomeofstereotacticbrachytherapywithtemporaryiodine125seedsinpatientswithwhogradeiigliomas AT sebastiansiller longtermoutcomeofstereotacticbrachytherapywithtemporaryiodine125seedsinpatientswithwhogradeiigliomas AT clausbelka longtermoutcomeofstereotacticbrachytherapywithtemporaryiodine125seedsinpatientswithwhogradeiigliomas AT niklasthon longtermoutcomeofstereotacticbrachytherapywithtemporaryiodine125seedsinpatientswithwhogradeiigliomas AT silkebirgitnachbichler longtermoutcomeofstereotacticbrachytherapywithtemporaryiodine125seedsinpatientswithwhogradeiigliomas |